Academic literature on the topic 'Breast cancer, pregnancy, chemotherapy, radiotherapy'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Breast cancer, pregnancy, chemotherapy, radiotherapy.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Breast cancer, pregnancy, chemotherapy, radiotherapy"
1
Koca, Timur, Zuleyha Akgun, Serap Baskaya Yucel, Nihal Zerman Dag, and Mehmet Teomete. "Pregnancy a short time after multimodal therapy for bilateral breast cancer: A case report and review of literature." Journal of Oncology Pharmacy Practice 17, no. 4 (September 21, 2010): 440–43. http://dx.doi.org/10.1177/1078155210384755.
Full textAbstract:
Pregnancy occurring after multimodal therapy in a woman with breast cancer with a 1-year follow-up period is a relatively rare condition and has been defined as pregnancy-associated breast cancer. A patient can become pregnant after chemotherapy for breast cancer while she is on tamoxifen. However, the effects of tamoxifen on fetus and on the course of the pregnancy are still unknown. Here, we present a 39-year-old woman treated with chemotherapy and radiotherapy for bilateral breast cancer, and who became pregnant while taking tamoxifen.
2
IONESCU, Olivia, and Nicolae BACALBASA. "Gestational breast cancer. Surgical treatment, pregnancy and fetal outcome." Romanian Journal of Medical Practice 12, no. 2 (March 31, 2017): 16–22. http://dx.doi.org/10.37897/rjmp.2017.1.3.
Full textAbstract:
Background. Gestational breast cancer (GBC) is also known as pregnancy-associated breast cancer and it comprises all the breast cancers (BCs) which are diagnosed either during pregnancy or in the first year after delivery or during the lactation period. At present it has been confirmed that the breast malignancies are the most common forms of cancer in pregnant women with a constant increase in its incidence because of the continuous postpone in childbearing especially in women older than 40 years. However, when diagnosed during the pregnancy, the treatment modalities of the BC are complex and difficult to establish as it must be considered the impact of the treatment both on the child and the course of pregnancy. Purpose. Using an online search on Pubmed, our aim was to make a review of the treatment possibilities of a pregnant woman presenting a breast malignant tumor. We have concentrated our paper on the surgical treatment and the possibility of an oncoplastic reconstruction types, the facts of radiotherapy during pregnancy and the prognosis of the GBC particularly in women who opt to continue the pregnancy. A resume of the epidemiology of GBG is also presented. Method. The following key words have been on Pubmed introduced: ,,breast cancer’’, ,,pregnancy’’, ,,staging”, ,,chemotherapy” and ,,radiotherapy”. As mentioned above, we have tried to select the BC cases diagnosed and treated during pregnancy for which the decision of the patient was to continue the pregnancy in spite of the diagnosis. We further aimed to present the prognosis of the pregnancy-associated BC, namely the pregnancy and fetal outcome, and to investigate if the decision to terminate the pregnancy is associated with a survival benefit. Conclusion. The surgical treatment of pregnancy-associated BC does not differ from that of non-pregnancy BC. Axillary LN-dissection is permitted while the data on the safety of sentinel-LN are still poor. Elective termination of the pregnancy has no impact on the overall survival of the patient.
3
Upadhyay, Ruchi, Qurat-Ul-Ain Butt, Abraham Hamaoui, Cassandra Henderson, Sydney McCalla, and Hamid Gilak. "Triple Negative Breast Cancer in Pregnancy and Postpartum: Two Case Reports in Hispanic Women." Case Reports in Obstetrics and Gynecology 2015 (2015): 1–4. http://dx.doi.org/10.1155/2015/856931.
Full textAbstract:
Objective. Despite studies suggesting that triple negative breast cancer is more often seen in women of African ancestry, we report here two cases of pregnancy associated triple negative breast cancer in Hispanic women.Cases. Case one is a 37-year-old female para 2-0-0-2, who presented with a left breast mass, at 19 weeks of gestation, the biopsy of which reported an invasive ductal carcinoma, found to be triple receptor negative. The patient underwent chemotherapy during the pregnancy and was delivered with a cesarean at 37 weeks for obstetric indication. After delivery, the patient completed her chemotherapy that was followed by radical mastectomy and radiotherapy. Case two is a 28-year-old female para 6-0-1-5, who presented while breast-feeding with signs and symptoms of mastitis, and an engorged and tender right breast, five months postpartum. However, the sonogram revealed a fluid filled cavity. Aspiration and cytology did not reflect an infection and were negative for malignancy. High suspicion and lack of improvement led to biopsy that identified an invasive ductal carcinoma, found to be triple negative. The patient underwent chemotherapy followed by modified radical mastectomy.Conclusions. Triple negative breast cancer, during pregnancy or postpartum, poses a unique challenge and requires a multidisciplinary team to optimize treatment for these women.
4
Galati, Francesca, Valentina Magri, Paula Andrea Arias-Cadena, Giuliana Moffa, Veronica Rizzo, Marcella Pasculli, Andrea Botticelli, and Federica Pediconi. "Pregnancy-Associated Breast Cancer: A Diagnostic and Therapeutic Challenge." Diagnostics 13, no. 4 (February 7, 2023): 604. http://dx.doi.org/10.3390/diagnostics13040604.
Full textAbstract:
Pregnancy-associated breast cancer (PABC) is commonly defined as a breast cancer occurring during pregnancy, throughout 1 year postpartum, or during lactation. Despite being a rare circumstance, PABC is one of the most common types of malignancies occurring during pregnancy and lactation, with growing incidence in developed countries, due both to decreasing age at onset of breast cancer and to increasing maternal age. Diagnosis and management of malignancy in the prenatal and postnatal settings are challenging for practitioners, as the structural and functional changes that the breast undergoes may be misleading for both the radiologist and the clinician. Furthermore, safety concerns for the mother and child, as well as psychological aspects in this unique and delicate condition, need to be constantly considered. In this comprehensive review, clinical, diagnostic, and therapeutic aspects of PABC (including surgery, chemotherapy and other systemic treatments, and radiotherapy) are presented and fully discussed, based on medical literature, current international clinical guidelines, and systematic practice.
5
Poggio, Francesca, Marco Tagliamento, Chiara Pirrone, Davide Soldato, Benedetta Conte, Chiara Molinelli, Maurizio Cosso, Piero Fregatti, Lucia Del Mastro, and Matteo Lambertini. "Update on the Management of Breast Cancer during Pregnancy." Cancers 12, no. 12 (December 3, 2020): 3616. http://dx.doi.org/10.3390/cancers12123616.
Full textAbstract:
The diagnosis of breast cancer during pregnancy represents a challenging situation for the patient, her caregivers and physicians. Pregnancy adds complexity to oncological treatment planning, as many therapies can be potentially dangerous to the fetus. Therefore, a multidisciplinary approach is needed to offer a proper care for obtaining the best possible outcomes for the mother and the future child. Breast surgery is feasible throughout the pregnancy while radiotherapy should be postponed after delivery. Administration of chemotherapy is considered safe and can be given during the second and third trimesters, while it is contraindicated in the first trimester due to the high risk of fetal malformations. Endocrine therapy and targeted agents are not recommended during the whole pregnancy period; however, limited data are available on the use of the majority of new anticancer drugs in this context. The aim of the current review is to provide an update on the current state of art about the management of women diagnosed with breast cancer during pregnancy.
6
Kufel-Grabowska, Joanna. "Fertility and breast cancer." Oncoreview 6, no. 4 (December 30, 2016): 0. http://dx.doi.org/10.5604/01.3001.0009.5057.
Full textAbstract:
Breast cancer is the most common cancer among females worldwide. The mean age of breast cancer patients is > 60 yrs old, and it is seldom found in women < 40 yrs old (6.5%) and in very young women < 35 yrs old (0.6%). In young females, fertility and all its aspects are an additional therapeutic challenge. Before initiating treatment, the oncologist should offer effective contraception to be applied throughout the therapy, bearing in mind that fertility preservation is of utmost importance. When it comes to breast cancer in pregnancy, the attending physician should use a therapy which is safe for both the mother and the foetus. Chemotherapy, radiotherapy, hormonal therapy and immunotherapy can, to a lesser or greater degree, damage the ovarian function resulting in amenorrhea in women < 50 yrs (33–76%). However, owing to fertility preservation strategies, more and more pregnancies are successful, even in breast cancer survivors.
7
Simionescu, Anca A., Alexandra Horobeț, Lucian Belaşcu, and Dragoş Mircea Median. "Real-World Data Analysis of Pregnancy-Associated Breast Cancer at a Tertiary-Level Hospital in Romania." Medicina 56, no. 10 (October 6, 2020): 522. http://dx.doi.org/10.3390/medicina56100522.
Full textAbstract:
Background and objectives: Breast cancer is among the most common cancer types encountered during pregnancy. Here, we aimed to describe the characteristics, management, and outcomes of women with pregnancy-associated breast cancer at a tertiary-level hospital in Romania. Material and Methods: We retrospectively and prospectively collected demographic, oncological, and obstetrical data for women diagnosed with cancer during pregnancy, and who elected to continue their pregnancy, between June 2012 and June 2020. Complete data were obtained regarding family and personal medical history and risks factors, cancer diagnosis and staging, clinical and pathological features (including histology and immunohistochemistry), multimodal cancer treatment, pregnancy management (fetal ultrasounds, childbirth, and postpartum data), and infant development and clinical evolution up to 2020. Cancer therapy was administered following national guidelines and institutional protocols and regimens developed for non-pregnant patients, including surgery and chemotherapy, while avoiding radiotherapy during pregnancy. Results: At diagnosis, 16.67% of patients were in an advanced/metastatic stage, while 75% were in early operable stages. However, the latter patients underwent neoadjuvant chemotherapy rather than up-front surgery due to aggressive tumor biology (triple negative, multifocal, or HER2+). No patient achieved complete pathological remission, but only one patient relapsed. No recurrence was recorded within 12 months among early-stage patients. Conclusions: In this contemporary assessment of real-world treatment patterns and outcomes among patients with pregnancy-associated breast cancer, our findings were generally consistent with globally observed treatment outcomes, underscoring the need for a multidisciplinary team and reference centers.
8
Wijaya, Ramesh, Wei Sean Yong, Allen WY Yeo, and Diana TH See. "Managing Breast Cancer Diagnosed in First Trimester Pregnancy: A Case Report." Annals of the Academy of Medicine, Singapore 36, no. 12 (December 15, 2007): 1024–27. http://dx.doi.org/10.47102/annals-acadmedsg.v36n12p1024.
Full textAbstract:
Introduction: Breast cancer is the most common malignancy in pregnant women, occurring at a rate of about 1 in 3000 pregnancies. Unfortunately, this will sometimes occur during the firsttrimester of pregnancy and this situation warrants discussion of management options with regard to the mother and child, especially with the current trend of deferring child bearing to a later age. Clinical Picture: We present a 34-year-old primigravida who had a breast lump prior to confirmation of her pregnancy and received her diagnosis of invasive breast cancer at 7 weeks’ amenorrhoea. The oncologic management options of this pregnant patient with breast cancer are discussed. Treatment: The patient eventually opted to undergo wide excision of the breast cancer with sentinel lymph node biopsy and possible axillary clearance together with termination of her pregnancy. Results: The patient successfully underwent surgery for her breast cancer and was subsequently treated with adjuvant therapy as per normal protocol for a non-pregnant patient. Conclusion: The management of breast cancer and pregnancy occurring concurrently is a complex problem fraught with many dilemmas for both the medical team, the patient and her family. The option chosen must involve a multidisciplinary team and have full informed consent of the patient. Key words: Adjuvant chemotherapy, Radiotherapy
9
Pereira de Godoy, Jose Maria, Lívia Maria Pereira de Godoy, and Maria de Fatima Guerreiro Godoy. "Evolution Of Subclinical Systemic Lymphedema In-Patient With Lipedema And Axillary Dissection." International Journal of Medical Science and Clinical invention 7, no. 07 (July 4, 2020): 4868–70. http://dx.doi.org/10.18535/ijmsci/v7i07.02.
Full textAbstract:
Background: The surgical treatments of breast cancer associated or not with axillary drainage and radiotherapy constitute the main cause of secondary upper limb lymphedema. Obesity is a particularly aggravating aspect in patients with lymphedema. Novel concepts of subclinical systemic lymphedeman and clinical systemic lymphedema have recently been described. The aim of the present study was to evaluate the evolution of subclinical systemic lymphedema to upper limb lymphedema following treatment for breast cancer. Case: A 36-year-old female patient had been submitted to treatment for breast cancer involving left-side mastectomy and lymph node drainage during a pregnancy three years earlier. She had undergone both chemotherapy and radiotherapy. The patient had a portacath in the right arm for chemotherapy, which was removed after the first evaluation. She was submitted to bioelectrical impedance analysis, which revealed an increase in intracellular and extracellular water and body water in all limbs and the trunk above the normal range. The patient returned approximately two years after the initial evaluation, complaining of edema in the left arm. Conclusion: The treatment of breast cancer in patients with lipedema could lead to the development of subclinical lymphedema in patients with a BMI less than 30 kg/m2. Therefore, such conditions constitute a warning sign for the development of lymphedema.
10
Alfasi, Ayelet, and Irit Ben-Aharon. "Breast Cancer during Pregnancy—Current Paradigms, Paths to Explore." Cancers 11, no. 11 (October 28, 2019): 1669. http://dx.doi.org/10.3390/cancers11111669.
Full textAbstract:
Breast cancer is the most common form of malignancy in pregnant women. The prevalence of pregnancy-associated breast cancer (PABC) is up to 0.04% of pregnancies and is expected to rise in developed countries. PABC represents a unique clinical scenario which requires a delicate balance of risks and benefits for both maternal and fetal well-being. Currently, there is paucity of data regarding the short- and long-term outcomes of in-utero exposure to anti-neoplastic agents. In general, when possible, treatment for PABC should follow the same guidelines as in non-pregnant patients. Surgery, including sentinel lymph node biopsy, is possible during all trimesters of pregnancy. Radiotherapy is contraindicated during pregnancy, although it might be considered in highly selected patients based on risk–benefit assessment. Evidence supports that administration of chemotherapy may be safe during the second and third trimesters, with cessation of treatment three weeks prior to expected delivery. Currently, hormonal therapy and anti-HER2 agents are contraindicated during pregnancy and should be postponed until after delivery. Prematurity is associated with worse neonatal and long-term outcomes, and thus should be avoided. While current data on the long-term effects of anti-neoplastic treatments are reassuring, grade of evidence is lacking, hence additional large prospective studies with long-term follow-up are essential to rule out any treatment-induced adverse effects.
Dissertations / Theses on the topic "Breast cancer, pregnancy, chemotherapy, radiotherapy"
1
CIRIELLO, ELENA. "Tumore della mammella in gravidanza: fattori di prognosi e risultati clinici in uno studio caso-controllo." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2011. http://hdl.handle.net/10281/20079.
Full textAbstract:
PURPOSE: Pregnancy-associated breast cancer (PABC) is one of the most common malignancies during pregnancy (one in 3,000 pregnancies); up to 3% of breast cancers are diagnosed in pregnancy.
Our objective is to verify if women with pregnancy-associated breast cancer (PABC) have poorer outcome than nonpregnant women with breast cancer.
METHODS: We register in a Cancer and Pregnancy Registry the clinical course, treatment, and disease outcome of nonpregnant women with breast cancer and of women with PABC.
In a retrospective control study (2:1) we compared the women with PABC (65 cases) with nonpregnant women with breast cancer (130 cases) matched for age at diagnosis, stage of disease and year of surgery.
RESULTS: Of 65 cases diagnosed, 45 was early cancer and 20 was locally advanced or metastatic cancer. The pregnancy ended in a spontaneus miscarriage in 3 patients (5%), and 15 (23%) pregnancy were interrupted.
The mean age at diagnosis was 36 ± 4.2 years. Treatment was started during pregnancy in 32 (49%) patients and after delivery in 33 (51%) patients.
Of 65 cases, 49 (75%) women received chemotherapy, 52 (80%) women received radiotherapy and 46 (71%) women were diagnosed with an estrogen/progesterone receptors-positve tumor.
The mean gestational age at delivery was 35.4 ± 2.1 weeks.
Eleven women (17%) are deceased and 21 (32%) progressed with a median follow-up of 48 months.
There are no difference between cases and control in term of biological features of cancer and treatment.
CONCLUSIONS: The treatment of breast cancer in pregnancy should be executed by experienced specialists in a multidisciplinary setting and should adhere as closely as possible to standard protocols.
As more women postpone child bearing until later in life, it is expected that PABC will become increasingly more common.
The prognosis in pregnant women with breast cancer is worse than in nonpregnant women.
2
Brisbois, Maryellen D. "Chemotherapy-Induced Premature Menopause Among Latina Women With Breast Cancer: An Interpretive Description: A Dissertation." eScholarship@UMMS, 2013. https://escholarship.umassmed.edu/gsn_diss/29.
Full textAbstract:
The description and interpretation of Latinas’ experience with chemotherapyinduced premature menopause from breast cancer treatment were explored in this study, which utilized an interpretive descriptive method from a feminist lens, and Knobf’s (1998, 2002) “Carrying on” theory. The specific aims of the study and the interview questions were guided by the state of the science literature. Overall, the impact of physiological effects, psychosocial effects, barriers, influencing factors that made their experience easier or harder, and how participants adjusted to a cancer diagnosis, treatment course, and menopause transition were described as bigger than the menopause experience alone. Participants also described a period of uncertainty or “ever-changing landscape” that began at the time of diagnosis and continued through survivorship. The impact of information, access to healthcare, acculturation levels, support, and a sense of control were elucidated as important factors in “working through” the experience. A range of collateral data sources were employed. Study limitations and future implications for practice, research, and health policy were demarcated.
3
Cutter, David J. "Radiation-related cardiovascular disease following cancer therapy." Thesis, University of Oxford, 2014. http://ora.ox.ac.uk/objects/uuid:3f02ca87-530d-4ee7-9382-4b457bec62b5.
Full textAbstract:
Introduction: Some cancer survivors are known to have an elevated risk of morbidity and mortality from cardiovascular disease. An important cause of this elevated risk is recognised to be irradiation of normal tissues during radiotherapy received as part of cancer therapy. There are substantial difficulties in studying radiation-related cardiovascular disease (RRCD). The reasons for this include the complexities of measuring radiation normal tissue doses retrospectively and the prolonged latencies of many of the cardiovascular endpoints. A variety of complimentary research methodologies can help provide additional knowledge to guide the appropriate management of patients treated in the past and of new patients in the future. Methods: 1) A cohort study of mortality from circulatory disease in the nationwide British Childhood Cancer Survivor Study (BCCSS). 2) A case-control study of valvular heart disease (VHD) in Dutch Hodgkin lymphoma (HL) survivors, including retrospective radiation dosimetry to estimate the radiation dose to heart valves. 3) A dosimetric study of cardiovascular radiation doses in patients entered into the UK NCRI Lymphoma Study Group RAPID trial, including predictions of 15-year cardiac mortality using innovative methods. 4) A modelling study to predict mean whole heart dose (MWHD) from involved field radiotherapy (IFRT) for HL using anatomical measures. 5) A prospective study using cardiovascular magnetic resonance (CMR) imaging to characterise the heart in women receiving radiotherapy for breast cancer. Results: 1) The risks of all types of circulatory mortality are elevated in survivors of childhood cancer. The absolute excess risks continue to increase 40+ years following diagnosis. The risk of death from cardiomyopathy and heart failure increased substantially with the introduction of anthracycline chemotherapy. There is no evidence of a reduction in risk of circulatory mortality in more recent eras of diagnosis. 2) There is a strong relationship between estimated radiation dose to the affected heart valve and the risk of subsequent VHD (p<0.001). This effect was modelled to allow prediction of the risk of VHD. 3) A proportion of patients treated with IFRT received a substantial cardiac radiation dose (MWHD = 8.8 Gy, SD = 5.6) but, on average, the predicted 15-year cardiac mortality following treatment is low (absolute risk 0.2%, range 0.0 to 2.7%). 4) It is possible to estimate the mean whole heart dose from IFRT prior to detailed radiotherapy planning based on pre-treatment diagnostic imaging to an accuracy of 5-6% of the prescribed dose. 5) Although women received low cardiac doses (MWHD = 1.5 Gy, SD = 0.8) and have a low predicted risk of cardiac radiation-related morbidity and mortality, there is some evidence of subclinical effects on strain and strain rate imaging of the anterior portions of the left ventricle that receive the highest radiation dose. Conclusions: Using a variety of methods these studies have all succeeded in adding to knowledge about the nature, magnitude and timing of RRCD. This knowledge can be used to help the future management of cancer patients. In addition, each of the studies has natural and planned extensions and will continue to contribute further knowledge into the future.
4
Potter, Ann Marie. "THE IMPACT OF CHEMOTHERAPY AND RADIOTHERAPY FOR BREAST CANCER ON COGNITION AND FUNCTIONAL PERFORMANCE: A COMPARATIVE ANALYSIS OF SURVEY DATA TAKEN AT THREE TIME POINTS POST-TREATMENT." VCU Scholars Compass, 2017. https://scholarscompass.vcu.edu/etd/5174.
Full textAbstract:
Cognitive impairment related to treatment for breast cancer, affects as many as 75% of patients in study samples (Jansen, Cooper, Dodd & Miaskowski, 2011). Deficits in the cognitive domains of short-term memory, attention, speed of information processing, judgment, reasoning, spatial attention, and verbal memory have been documented. The extent to which these deficits impact functional performance within this population has not yet been quantified. The purpose of this study was to investigate the impact of breast cancer on self-reported cognition and functional performance in the six months post-completion in two groups of breast cancer survivors, a chemotherapy group and chemotherapy and radiotherapy group. Cognition and functional performance were measured with the Patient Reported Outcomes Measurement Information System (PROMIS®). Cognition was measured in terms of abilities and concerns. Functional performance measures addressed the constructs of physical function, ability to participate in social roles and activities, and satisfaction with participation in social roles and activities.
Sixteen female participants (ages 28-45) completed online surveys three weeks following the conclusion of chemotherapy or radiotherapy and three and six months later. Linear mixed-effects models were used to analyze changes over time within groups and compare differences between groups. Over the six months post-treatment the chemotherapy group had a significant improvement in physical function (p=.0178), and the chemotherapy + radiotherapy group showed significant gains in the ability to participate in social roles and activities (p=.0447). Fatigue was a significant factor in the chemotherapy + radiotherapy group (p=.015). No significant differences between groups were noted for changes in cognition, functional performance or psychosocial factors.
This research provides insight into self-reported changes in cognition and functional performance in the six months following breast cancer treatment. Cognition and functional performance appear to be interrelated and impacted by a constellation of factors that occupational therapists and oncology providers need to be aware of in order to best support cancer survivors in the resumption of occupations after treatment. A comprehensive approach to assessment and intervention that considers the complexity of cognitive performance as it relates to physical capacity and concurrent symptoms is recommended.
5
Huang, Ming Ming. "Effects of Post-operative Adjuvant Chemotherapy and Radiotherapy on Serum Copper and Zinc Status in Stage II Breast Cancer Patients." 2004. http://www.cetd.com.tw/ec/thesisdetail.aspx?etdun=U0007-1704200714553714.
Full text
6
Ming, Huang Ming, and 黃明明. "Effects of Post-operative Adjuvant Chemotherapy and Radiotherapy on Serum Copper and Zinc Status in Stage II Breast Cancer Patients." Thesis, 2004. http://ndltd.ncl.edu.tw/handle/06969937429915668897.
Full textAbstract:
碩士臺北醫學大學
保健營養學系
92
Abstract In Taiwan, the incidence rate of female breast cancer has been increasing gradually every year, and has been the 4th leading cause of cancer death. This study was aimed to explore the effect of postoperative adjuvant chemotherapy (C/T) and radiotherapy (R/T) on serum copper, zinc, Cu/Zn ratio and RBC-SOD in female breast cancer patients. In the meantime, we analyzed the dietary intake and body weight change to understand whether the serum trace elements status of the patients were influenced by diet, C/T, or R/T. Results obtained from this study may provide some information for adequate nutrition support in clinical practice in the future. The results showed that serum copper, zinc, Cu/Zn ratio and RBC-SOD were not significantly different before and after C/T and R/T treatment in patients. During postoperative treatment, Cu/Zn ratio did not show significant difference, but a significantly positive correlation trend between several measurement was noted. Dietary zinc and protein intake did not significantly correlated with serum copper and zinc status. Calorie intake increased 300-100 Kcal/d and body weight showed an elevated trend with 3% increase after the postoperative treatment started, however, there were no obvious changes than before. The percentage of macronutrients intake were in normal ranges. Protein intake increased from 1.17 g/ kg BW to 1.39 g/kg BW when postoperative treatment began, and zinc intake was higher during treatment period, but showed no significant difference. The level of zinc intake was below RDNA before and after treatment. In conclusion, postoperative adjuvant chemotherapy and radiotherapy did not affect serum copper , zinc, Cu/Zn ratio and RBC-SOD in stage II breast cancer patients who take balance diet containing adequate amount of copper and zinc. Keywords: breast cancer, chemotherapy, radiotherapy, Cu, Zn, SOD
7
Gonçalves, José Francisco da Silva. "Oral complications of cancer treatment in patients with breast neoplasm : a retrospective observational study in a hospital setting." Master's thesis, 2015. http://hdl.handle.net/10400.14/19512.
Full textAbstract:
A incidência global de cancro, particularmente cancro da cama, tem vindo a aumentar nas últimas décadas, com a cavidade oral a ser um dos locais afectados por efeitos adversos, nomeadamente osteoquimionecrose, devido ao uso de fármacos como os bifosfonatos e mais recentemente anticorpos monoclonais.
Objectivos: Analisar e caracterizar as complicações orais associadas ao tratamento oncológico em doentes com neoplasia da mama.
Materiais e Métodos: Um estudo observacional retrospectivo foi realizado. Os registos clínicos de 32 pacientes a receberem quimioterapia e radioterapia no Hospital Santos Silva(Centro Hospitalar de Vila Nova de Gaia /Espinho). De seguida todos os pacientes serão submetidos a examinação intra-oral e a um questionário. Tipo de Tumor, Estadio Tumoral , Esquemas Terapeuticos e manifestações orais serão determinados e a análise estatistica realizada usando SPSS 21.0.
Resultados : Foi obtida uma amostra de 32 pacientes, Carcinomas Invasivos foram os mais observados com uma incidência de 56.25% (n=18). Estadio IIIA foi o mais comum entre os vários estadios observados com uma incidência de 25% (n=8). FEC, 46.9% (n=15), foi o esquema terapêutico de quimioterapia mais utilizado. Disgeusia foi a manifestação oral mais frequente com uma incidência de 81.3%.
Conclusão: O conhecimento deste tipo de complicações decorrentes do tratamento do cancro da mama por parte dos pacientes é bastante reduzido e desvalorizadas pelos mesmos. É da nossa opinião que mais estudos sobre a ocorrência destas complicações durante o tratamento oncológico sejam realizados pelas entidades competentes de modo a permitirem o aumento da qualidade de vida do doente oncológicoThe overall incidence of cancer, particularly breast cancer, has increased substantially over the last decades, with the oral cavity being one of the locations where side effects usually occur, namely osteochemonecrosis, as a consequence of the use of drugs such as bisphosphonates and, more recently, monoclonal antibodies. Purpose: To analyse and further characterise the main oral manifestations of cancer treatment associated with patients with breast neoplasm. Material and methods: A retrospective observational study as carried out. Records from 32 patients undergoing chemotherapy will be retrieved from the Hospital Santos Silva (CHVNG/E) files and reviewed. Patients will subsequently be observed and a questionnaire applied. Tumour type, stage, therapeutic regimens, and oral manifestations will be determined and a statistical analysis performed using SPSS 21.0. Results: A sample of 32 patients was obtained. Invasive Carcinoma were the most common breast neoplasm form with an incidence of 56.25% (n=18). Stage IIA was the most common with an incidence of 25 % (n=8). FEC, 46.9% (n=15), was the most employed therapeutic chemotherapy regimens. Dysgeusia was the most common oral complication observed with an incidence of 81.3% (n=26) Conclusion: The awareness for oral complications during breast neoplasm between patients is very low and undervalued by them. More study on the subject are necessary so that the quality of life for the oncological patient can be improved significantly.
Books on the topic "Breast cancer, pregnancy, chemotherapy, radiotherapy"
1
Veronique, Benk, and Canadian Coordinating Office for Health Technology Assessment., eds. Impact of radiation wait times on risk of local recurrence of breast cancer: Early stage cancer with no chemotherapy. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2004.
Find full text
2
1955-, Jatoi Ismail, and Singletary S. Eva, eds. Breast cancer: New concepts in management. Philadelphia: W.B. Saunders Co., 2003.
Find full text
3
Singletary, S. Eva. Breast cancer: Myths & facts : what you need to know. 3rd ed. Manhasset, NY: Oncology Pub. Group of CMP Healthcare Media, 2004.
Find full text
4
Breast cancer Mardi Gras: Surviving the emotional hurricane and showing my boobs to strangers. Bloomington, IN: AuthorHouse, 2013.
Find full text
5
Breast Cancer. Springer, 2012.
Find full text
6
Singletary, S. Eva. Breast Cancer. Springer London, Limited, 2012.
Find full text
7
A Journey through Cancer: A Woman Doctor's Personal Experience with Breast Cancer. iUniverse, Inc., 2004.
Find full text
8
Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff, and Madhumita Bhattacharyya. Breast cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0014_update_001.
Full textAbstract:
Thoracic cancer examines the epidemiology, aetiology, and role of screening and prevention in the reduction of deaths from lung cancer, the majority caused by cigarette smoking. The pathology and genetics of lung cancer, with particular note of the driver mutations, are followed by the symptoms and signs of the disease. Appropriate investigations are described to stage the tumour. The optimum treatment for localised non-small cell lung cancer (NSCLC) is surgical resection, followed in some cases by adjuvant chemotherapy. However, most cases present with disease too advanced for surgery, and for these chemotherapy and radiotherapy are appropriate. Metastatic NSCLC can be treated with platinum based doublet chemotherapy with modest palliative benefits. Metastatic NSCLC with specific driver mutations are amenable to control by targeted therapy. Locally advanced NSCLC is often treated with similar chemotherapy and radiotherapy, ideally administered concurrently, to achieve symptom relief but also improved survival rates. Short course simple radiotherapy offers symptom relief in patients not fit for chemotherapy. Patients with localised NSCLC who are not fit for surgery, may benefit from radical radiotherapy, particularly stereotactic radiotherapy. Small cell lung cancer (SCLC) is characterised by almost universal systemic spread, so that surgery is rarely appropriate. Staging is similar to NSCLC, and chemotherapy is the mainstay of treatment, usually cisplatin or carboplatin combined with etoposide. When possible, this is combined with concurrent thoracic irradiation covering all radiological sites of disease. Prophylactic cranial irradiation reduces the risk of CNS disease. Malignant pleural mesothelioma is caused by occupational asbestos exposure. Symptoms and signs, investigation and staging, and management are discussed. Thymic tumours, their pathology, presenting symptoms including paraneoplastic syndromes, investigation, staging and treatment are reviewed.
9
Adjuvant therapy for breast cancer. Cary, NC: Oxford University Press, 2001.
Find full text
10
Adjuvant Breast Cancer Treatment. Springer, 2009.
Find full textBook chapters on the topic "Breast cancer, pregnancy, chemotherapy, radiotherapy"
1
Tambas, Makbule, Kamuran Arslan Ibis, and Merdan Fayda. "Adjuvant Radiotherapy After Preoperative Chemotherapy." In Breast Cancer, 463–71. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-96947-3_20.
Full text
2
Amouzegar Hashemi, Farnaz. "Radiotherapy in Pregnancy-Associated Breast Cancer." In Advances in Experimental Medicine and Biology, 125–27. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-41596-9_16.
Full text
3
Ohri, Nisha, and Alice Ho. "Radiotherapy Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer." In Personalized Treatment of Breast Cancer, 171–86. Tokyo: Springer Japan, 2016. http://dx.doi.org/10.1007/978-4-431-55552-0_12.
Full text
4
Gursel, Bilge, and Ayfer Haydaroglu. "Interaction of Chemotherapy, Radiotherapy, and Timing." In Principles and Practice of Modern Radiotherapy Techniques in Breast Cancer, 59–70. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-5116-7_6.
Full text
5
Henderson, I. C., D. Hayes, M. A. Rose, S. Come, and J. Harris. "The Integration of Radiotherapy and Chemotherapy in the Treatment of Early Breast Cancer." In Breast Diseases, 416–35. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-73523-3_40.
Full text
6
Bawazir, Amen, Huda Basaleem, Ahmed Badheeb, and Gamal Abdul Hamid. "General Oncology Care in the Republic of Yemen." In Cancer in the Arab World, 321–38. Singapore: Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-7945-2_20.
Full textAbstract:
AbstractCancer is recognized nowadays as one of the important diseases in Yemen from the public health view. During the last three decades, remarkable changes in oncology health care services were observed in the country, mostly in urban areas. According to the Global Cancer Observatory of the International Agency for Research on Cancer, the total cases reported in the year 2020 was 16,476 new cases, and the top five reported cancers in the country were: breast cancer, colorectum, leukemia, stomach, and non-Hodgkin lymphomas. This rank of cancer types is probably unlike what exists in the neighboring Gulf countries. Oncology services in the country suffer from very limited radiotherapy care, chemotherapy centers, as well as many essential diagnostic laboratories for cancer.
7
Crezee, J., A. Bakker, R. Zweije, M. W. Kolff, H. J. G. D. van den Bongard, G. van Tienhoven, and H. P. Kok. "Combined Use of wIRA and Microwave or Radiofrequency Hyperthermia." In Water-filtered Infrared A (wIRA) Irradiation, 97–106. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-92880-3_7.
Full textAbstract:
AbstractClinical hyperthermia (i.e., heating of tumor tissue to 40–43 °C) is used in clinical oncology to enhance the therapeutic effect of chemotherapy and radiotherapy. Most recurrent breast cancer and melanoma lesions reach up to a few cm deep and can be effectively treated with currently available superficial hyperthermia devices using infrared or microwave radiation. Effective heating of more challenging and complex semi-superficial or semi-deep tumor lesions, including intact breast or lesions near silicone implants, requires dedicated treatment protocols. Herein, new treatment protocols are presented, which combine simultaneous and consecutive use of different wIRA, microwave, and radiofrequency hyperthermia devices. Examples are included, showing the clinical setup, applicator choice, and invasive and noninvasive thermometry.
8
Zola, P., C. Macchi, G. Parpinel, B. Masturzo, M. Laudani, E. Potenza, and M. Mitidieri. "Breast Cancer and Pregnancy." In NEOPLASIA and FERTILITY, 86–105. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815050141122010006.
Full textAbstract:
The association between breast cancer and pregnancy is defined as detecting breast cancer during pregnancy or within one year after delivery. The diagnosis is often difficult and delayed. It is based on clinical examination, radiological exams (ultrasound and/or RM) and biopsy of the suspected lesion. The staging examinations should be performed only if any change in therapeutic decisions or clinical practice could be made or in the presence of a high risk of distant metastases. The treatment includes surgery, radiotherapy, chemotherapy, hormonal therapy and molecular targeted therapy, and it should be as close as possible with the standard protocols of non-pregnant patients and should be discussed with a multidisciplinary team. It is important to start the treatment as soon as possible, with the exception of term pregnant patients, for whom it can be postponed after delivery. The major fetal complications seem to be related to prematurity, and the type of delivery depends on obstetrics indication. The delivery should be planned at least three weeks after the infusion of chemotherapy, and the treatment generally could be restarted one week after the cesarean section and immediately after a vaginal delivery. The apparent poor outcome in pregnant women can be explained by the delayed diagnosis and/or treatment and the biological characteristics of the tumor (often of high grade and triple negative). Finally, when the treatment is planned, reproductive counseling should always be proposed to young patients immediately after diagnosis in order to plan the best fertility preservation strategies
9
Baig, Mirza. "Breast Cancer." In Practical Radiotherapy and Chemotherapy Planning, 234. Jaypee Brothers Medical Publishers (P) Ltd., 2018. http://dx.doi.org/10.5005/jp/books/13056_31.
Full text
10
Baig, Mirza. "Palliative Treatment in Breast Cancer." In Practical Radiotherapy and Chemotherapy Planning, 240. Jaypee Brothers Medical Publishers (P) Ltd., 2018. http://dx.doi.org/10.5005/jp/books/13056_32.
Full textConference papers on the topic "Breast cancer, pregnancy, chemotherapy, radiotherapy"
1
Nascimento, Ranier Colbek, and Sabrina Ribas Freitas. "A 29-YEAR-OLD PREGNANT WOMAN WITH METASTATIC BREAST CANCER: A CASE REPORT." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2107.
Full textAbstract:
Pregnancy-associated breast cancer (PABC) is defined as a breast cancer diagnosed during pregnancy, lactation, or in the first postpartum year. PABC is a rare complication that occurs in approximately 0.01% to 0.03% of all pregnancies. The difficulty in diagnosis worsens the prognosis. D.G., 29-year-old, female, noted a mass in her right breast in June 2020. One month later with 13+4 weeks’ gestation, she presented to the obstetrics emergency with recurrent episodes of lower back pain. She was released home with pain relief and was instructed to realize a mammography due to the presence of a 4-cm mass on physical examination of the right breast. Patient returned 12 days later with severe low back pain, a BIRADS 4C mammography, and multiple liver lesions in total abdomen ultrasound. Core-needle biopsy demonstrated a stage II invasive ductal carcinoma with hormone receptors positive and human epidermal growth factor receptor 2 positive. There is involvement of the axilla and intramammary lymph nodes. Magnetic resonance imaging of the lower back and sacroiliac joint was performed and found multiple lesions suspected of metastasis in the inferior thoracic vertebrae, lumbar vertebrae, sacrum, ilium, and femurs. Computed tomography (CT) of the thorax identified a 2.3×1.8 cm irregular lesion in the right breast compatible with the primary neoplasm. Chemotherapy was initiated till she was 31 weeks’ gestation. After childbirth, she reinitiates chemotherapy. Three months later, the patient has convulsive episodes. Cranial CT was done and found multiple lesions compatible with brain metastasis, so she initiated brain radiotherapy. PABC can present itself as a challenging situation with nonspecific symptoms and at an advanced stage. Therefore, it is important to have the PABC in our list of differential diagnoses in this patient.
2
Yoshimura, Adriana Akemi, André Mattar, Bruna S. Mota, Carlos Elias Fristachi, Eduardo Carvalho Pessoa, Felipe Eduardo Andrade, Giuliano Tosello, et al. "A MULTICENTRIC STUDY ON BREAST CANCER IN ULTRA YOUNG WOMEN: III – THERAPEUTIC ASPECTS AND ONCOLOGICAL OUTCOMES." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1091.
Full textAbstract:
Introduction: We have originally introduced the concept of ultra young women (UYW), defined as age ≤30 years old. It is generally accepted that UYW patients with breast cancer (BC) share some unfavorable outcomes and the patients are faced with family and professional problems, and unique quality of life issues, including loss of fertility, contraception, pregnancy, sexuality, cancer during pregnancy, body image and emotional distress, that complicate treatment decisions making. Objectives: Study the type of surgical and systemic treatment and oncologic outcomes in UYW with BC. Methods: We conducted a multicentric, observational, retrospective study of consecutive BC UYW patients. Only patients with infiltrating BC were included. Nine Mastology Centers located in the State of São Paulo participated. The following data were recorded: type of surgery, chemotherapy, endocrinetherapy, and radiotherapy. Individual oncologic evolution was analyzed and the patients were classified as alive without disease (AWD), alive with local recurrence (ALR), alive with systemic recurrence (ASR), died from BC (DBC) or died from another cause (DOC). The research protocol was approved by the Ethics Committee of all Collaborative Centers. Results: Sixteen percent of UYW with BC underwent mastectomies, 10% nipple-sparing mastectomies and 16% breast conservative surgeries. About 50% had immediated breast reconstruction. Sentinel node biopsy was performed in 24%. 18% had more than four compromised LNs, 8% with extracapsular leak. 37% received adjuvant or palliative chemotherapy. 61% were submitted to irradiation. 54% had adjuvant hormonetherapy. The mean time of follow-up was 41.5 months (1.5-207). It was observed that 59% were AWD, 1% ALR, 7% ASR and 23% DBC, unfortunately standing out the elevated contingent of BC-related deaths. Conclusions: BC therapy in UYW were tailored according to individual characteristics, but the oncological outcomes in this age range at the moment could be considered unfavorable.
3
Ramalho, Tarciane Campos, Rafael Victor Moita Minervino, IsaIbela Campos Ramalho, Jean Fabricio de Lima Pereira, and Og Arnaud Rodrigues. "METAPLASTIC CARCINOMA OF THE BREAST WITH CHONDROID-TYPE MESENCHYMAL DIFFERENTIATION: A CASE REPORT." In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1055.
Full textAbstract:
Metaplastic breast carcinoma (MpBC) is a rare and morphologically diverse group of tumors in which a variable proportion or the entire tumor is composed of nonglandular epithelium or mesenchymal cells. It is defined by the histological presence of at least two cellular types, typically epithelial and mesenchymal components. It is composed of ductal, squamous, and/or chondroid, and spindle elements, with squamous cell carcinoma being the most frequent histological subtype. MpBC represents 0.2%–5% of all breast cancers and it is very aggressive. This type of breast cancer is typically triplenegative and is therefore not targetable with hormone therapy or anti-HER2 therapies, leaving only chemotherapeutics for management. MpBCs are known for their aggressive course and poor response to chemotherapy. PDL1/PD1 expression is a predictor of the effectiveness of immune checkpoint therapy in breast cancer. Finally, there are currently no standardized treatment guidelines specifically for MpBC2. A 42-year-old female patient, lactating, who had her only pregnancy at age 40, visited a Mastology Clinic on July 16, 2019, complaining of huge left breast pain. She did not know about her family background, as she was adopted. On physical examination, she had lactating breasts and two palpable lumps of hard consistency, contiguous, and mobile in the upper outer quadrant of the left breast, measuring 3 and 2.5 cm. Mammography described dense breasts, with no other changes and breast ultrasound revealed two solid nodules, measuring 2.7 and 0.6 cm, and a simple cyst measuring 3.4 cm, all of which were contiguous in the upper outer quadrant of the left breast — BIRADS 4. A fine-needle aspiration puncture was performed in the simple cyst, with a histopathological result of poorly differentiated malignant neoplasm with pleomorphic focus, and a core-needle biopsy, with histopathological result of breast tissue infiltrated by pleomorphic malignant neoplasm. The immunohistochemical analysis showed positive for pan cytokeratin AE1/AE3 and negative for CD45, S100, myogenin, and myodio; bringing the conclusion of poorly differentiated carcinoma, suggestive of MpBC. She received neoadjuvant chemotherapy, with doxorubicin + cyclophosphamide, but had rapid local tumor progression. A new ultrasound revealed a heterogeneous and partially delimited mass, measuring 8.8×6.1 cm — BIRADS 6. The patient underwent a left total mastectomy and axillary lymph node dissection on September 23, 2019 — without breast reconstruction, and confirmed invasive metaplastic carcinoma with chondroid-type mesenchymal differentiation, measuring 7 cm, histological grade III, nuclear grade III, associated with solid and cribriform ductal carcinoma in situ, with comedonecrosis — grade III; free surgical margins, but with axillary lymph node metastasis (8/20). The immunohistochemical analysis of the surgical specimen revealed a triple-negative carcinoma: estrogen and progesterone receptors negative, and HER2 negative. The patient had a good postoperative recovery and received radiotherapy (50 Gy). Thereafter, she received adjuvant chemotherapy with capecitabine, within which she evolved with axillary, supraclavicular, and pulmonary lymph node metastasis. The PDL1 marker showed a negative result; therefore, palliative paclitaxel and bevacizumab were prescribed. The patient rapidly evolved with worsening of the lung lesions and was hospitalized on March 9, 2020, with serious dyspnea, progressing to death on March 19, 2020.
4
Pasetto, Camila Vitola, Diego Wallace Nascimento, Gabriela Bezerra Nóbrega, and José Roberto Filassi. "AXILLARY ACCESSORY BREAST SARCOMA IN A YOUNG PATIENT." In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1007.
Full textAbstract:
The accessory breast tissue in the axillary region is rare, but as there is breast tissue, there is the possibility of pathological degeneration. With an even greater rarity, breast sarcoma is a diverse group of malignancies derived from mesenchymal tissues. The aim of this report was to describe a case of a young patient with sarcomatous neoplasia in the axillary accessory breast topography. Patient LPMS, 19 years old, female, admitted to the mastology service of the Hospital das Clínicas of the Universidade de São Paulo with a nodule realized in the left axillary region with progressive growth during pregnancy. The patient was healthy with a family history of a maternal aunt with breast cancer at 50 years old. At the clinical examination, she had an extensive tumor affecting the left axillary region measuring 10 cm with clinically negative axilla. Contralateral breast and axilla and supra-/infraclavicular fossas without abnormalities. In the initial mammogram, a hyperdense, oval, and indistinct nodule was found in the left axillary extension, measuring 10.8 cm. In breast magnetic resonance imaging, a heterogeneous mass in the left axillary extension is observed with irregular, lobulated margins, measuring 10.3×10×10.1 cm, heterogeneously and concentric by the contrast. Core biopsy was performed with the result of spindle cell mesenchymal neoplasm. In the systemic staging examinations, there was no evidence of a lesion suspected of distant metastasis. Vincristine 1.5 mg/m2 + Actinomycin D 0.45 mg/kg/day + Cyclophosphamide were prescribed to the patient. After six cycles with no clinical response, it was decided to switch the neoadjuvant chemotherapy to doxorubicin 25 mg/m2 and Ifosfamide 3,000 mg/m2 . After three cycles, the patient remains without a clinical response to neoadjuvant chemotherapy. It was decided to refer the patient to radiotherapy for axillary irradiation on the right, with a subsequent surgical approach. The patient underwent surgery with wide resection of the tumor and axillary lymph nodes. The anatomopathological examination showed sarcoma with immunohistochemistry suggestive of rhabdomyosarcoma measuring 19.3×14.8×14.7 mm with free margins and with sarcoma metastasis in one of the 21 dissected lymph nodes. The patient progresses well postoperatively. Accessory breast tissue has a very rare incidence in the population, with incidence rates of 1–2%. With regard to breast sarcoma, it is a very rare condition. It consists of a heterogeneous group of nonepithelial tumors originating from the mesenchymal tissues of the breast. They account for <1% of all breast malignancies and <5% of all sarcomas. Due to its rarity, current knowledge about breast sarcoma is limited and is mainly based on small retrospectives, case series, or case reports. Angiosarcoma, including secondary angiosarcoma from before breast radiation, is the most frequent type of breast sarcoma. As with other soft-tissue sarcomas, the primary breast sarcoma is associated with genetic conditions such as Li-Fraumeni syndrome, familial adenomatous polyposis, and type 1 neurofibromatosis. Therefore, breast sarcoma treatment generally follows the algorithms derived from trials of soft-tissue sarcomas in the chest wall, as has been done with the reported patient. Surgical treatment is the standard and most accepted treatment for breast sarcoma. The role of chemotherapy for breast sarcoma is also uncertain. There are no prospective studies that specifically assess the benefit of chemotherapy in adjuvant or neoadjuvant settings. Likewise, the benefit of radiotherapy in breast sarcoma is also very doubtful with evidence of benefit in large tumors and with positive margins after surgical resection.
5
Chaudhary, Sushila. "Successful pregnancy outcome in recurrent ovarian cancer." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685320.
Full textAbstract:
Incidences of ovarian cancer in pregnancy are increasing nowadays due to routine use of ultrasonography in first trimester and postponement of childbirth to an older age. Reported incidence of ovarian tumor in pregnancy is 1:1000 among them3.6% are malignant. We report a case of recurrent ovarian tumor with successful pregnancy outcome. She was a 26 yr old primi had ovarian cancer recurrence 2 year after primary surgery. In present pregnancy she was given chemotherapy with two doses of carboplatin, and had viable baby at 34 weeks of pregnancy. At present mother and baby are doing well and on regular follow-up at radiotherapy departments.
6
Campedelli, Ana Flávia de Paula Guerra, Nilceana Maya Aires Freitas, Thais Franco Simionatto, Nathalya Ala Yagi, Carolina Martinelli Bezerril, Jean Teixeira de Paiva, Edesio Martins, and Ruffo Freitas Junior. "RECIST EVALUATION OF THE USE OF SALVAGE RADIOTHERAPY IN LOCALLY ADVANCED BREAST CANCER REFRACTORY TO NEOADJUVANT CHEMOTHERAPY AND UNRESECTABLE." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1g15.
Full text
7
Berger, N., K. Fitzpatrick, and P. Klein. "Abstract P6-16-10: Is pregnancy testing during chemotherapy standardized?" In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-16-10.
Full text
8
Lee, S., and K. Shin. "Locoregional Recurrence with Breast Conservation Surgery and Radiotherapy after Neoadjuvant Chemotherapy." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-4120.
Full text
9
Meyer, Bianca dos Santos, Lélisa Pereira Oliveira, Carlos Antônio da Silva Franca, Reynaldo Real Martins Júnior, and Antônio Belmiro Rodrigues Campbell Penna. "IMPACT OF DELAYED ADJUVANT RADIOTHERAPY ON BREAST CANCER." In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1044.
Full textAbstract:
Introduction: In documents from the Brazilian Society of Radiotherapy, quantitative analysis revealed that radiotherapy sessions, when performed, have not been timely. The average waiting time between the diagnosis data and the start of radiotherapy has been, on average, 113.4 days — which can consistently affect the chances of being cured for many patients. In some regions, waiting time is even longer; not infrequently, patients are treated with outdated methods and unprecision machines. Radiotherapy in Brazil is in a critical situation, especially with regard to the care of patients assisted by the Brazilian Public Health System (SUS). The main problems that contribute to this scenario are related to inadequate description and poor installation capacity, both from the point of view of the number of devices and their geographic distribution. Objective: The aim of this study was to determine whether delaying the initiation of adjuvant radiotherapy is related to decreased survival in women with breast cancer. Methods: This is a retrospective, descriptive, and longitudinal study (cross section) of patients admitted to the CRI/IBO, Niterói, RJ, all from SUS. Through the review of medical records, 81 patients were selected. Only patients diagnosed with stage IIb (T3N0) breast malignancy according to the American Joint Committee on Cancer TNM 8th (AJCC) were included. The analysis was performed by the time taken to start the radiotherapy after the initial treatment, which was treated by conservative surgery followed by adjuvant chemotherapy. The cohort was divided into two groups according to the timing of radiotherapy after the initial treatment: 6 months. Results: In the data analysis, it was observed that 70 (86.4%) patients did not have disease recurrence, while 11 (13.6%) patients had tumor recurrence. The average time between the end of the last chemotherapy day and the start of adjuvant radiotherapy was 6.1 months (1–12/95%CI 5.5–6.8, SD±2.9). Referring patients to those who provide adjuvant radiotherapy at 6 months (group B), we have 36 patients (44.4%) in group A and 45 patients (55.6%) in group B. In group A (36 patients), 34 patients (94.4%) did not have tumor recurrence and 2 (5.6%) did have tumor recurrence. In group B (45 patients), 36 (80%) patients did not have tumor recurrence and 9 (20%) did have tumor recurrence, with p=0.0001. Bearing in mind that the objective of the study is disease-free survival in 5 years, the mean follow-up time of patients was 69.8 months (51–92/95%CI 68.2–71.3, SD±7.0). It was evaluated that patients who had adjuvant radiotherapy in less than 6 months had a longer survival than patients who had more than 6 months (p <0.001). Therefore, patients with a delay of more than 6 months in the initial adjuvant radiotherapy treatment had an impact on the 5-year disease-free survival. Conclusion: This study is not conclusive, but we were able to observe data that show a worsening in the patient’s survival and prognosis in relation to the delay in the radiotherapy treatment. However, the waiting time for radiotherapy should be as short as reasonably possible, as there is a possibility that this delay will cause worse disease control rates.
10
Sousa, Paulo Roberto Moura de, Mauricio de Aquino Resende, Ailton Joioso, Raimundo Jovita Araujo Bonfim, and Carlos Eduardo Witoslawski Breda. "FAT GRAFTING AFTER RADIOTHERAPY AND BREAST IMPLANT." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2095.
Full textAbstract:
This is a case report of reconstruction of the right breast and aesthetic improvement of the left breast, in a 52-year-old smoker woman, with bilateral breast cancer, neoadjuvant chemotherapy, modified radical mastectomy on the right, quadrantectomy with left, lymphadenectomy, and radiotherapy (RT). She sought the Amaral Carvalho Hospital for reconstructive surgery after 6 years of treatment. She underwent fat grafting (FG) with 237 mL on the right breast and 90 mL on the left breast and correction of the left areola. After 6 months, a retromuscular tissue expander was placed on the right, and remodeling of the breast and correction of the surgical scar are done on the left. After 8 months of achieving expansion with 350 mL of saline solution, the tissue expander was replaced by a wide base anatomical prosthesis with 485 mL and a 225 mL nonanatomical round prosthesis additive to the left. RT makes breast reconstruction difficult, as it gives better results with myocutaneous flaps. FG has a regenerative effect on irradiated tissues. Historically, reconstruction with autologous tissue is preferable to reconstruction with implantation in patients irradiated after mastectomy, as it presents less reoperation (16.6% vs. 37.0%, p<0.0001), total complications (30.9% vs. 41.3%, p <0.0001), and reconstructive failure (1.6% vs. 16.8%, p<0.0001). Radiodermite affects more than 90% of patients treated with RT. The dermis is affected with an increase in fibrosis, reduction in the number of capillaries, and irregular distribution. FG is able to reverse these changes. FG improves the characteristics of irradiated tissue, restores elasticity, and allows breast reconstruction with an implant without a myocutaneous flap.